Bart Neyns
Universitair Ziekenhuis Brussel · physician
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in glioblastoma
10
PubMed author-name match
Trials
Studies that name Bart Neyns as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07448831 · A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.Universitair Ziekenhuis Brussel · recruiting · Melanoma (Skin Cancer) · principal investigator
- N/ANCT05667857 · Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation TherapyUniversitair Ziekenhuis Brussel · recruiting · Cognitive Remediation, Neuropsychology, Quality of Life · principal investigator
- Ph2NCT04059224 · TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaUniversitair Ziekenhuis Brussel · completed · Stage IV Melanoma, Stage III Melanoma · principal investigator
- Ph1/Ph2NCT03754179 · Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaUniversitair Ziekenhuis Brussel · unknown · Melanoma · principal investigator
- Ph1NCT03747744 · Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)Universitair Ziekenhuis Brussel · unknown · Melanoma · principal investigator
- Ph1/Ph2NCT02941744 · A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesUniversitair Ziekenhuis Brussel · completed · Stage IIIC Skin Melanoma, Stage IV Skin Melanoma · principal investigator
- N/ANCT02907827 · Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.Universitair Ziekenhuis Brussel · unknown · Melanoma · principal investigator
- N/ANCT02673970 · Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced MelanomaUniversitair Ziekenhuis Brussel · unknown · Malignant Melanoma · principal investigator
- Ph1/Ph2NCT02316028 · Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)Universitair Ziekenhuis Brussel · completed · Liver Metastasis, Colorectal Cancer · principal investigator
- Ph2NCT01676779 · mRNA Electroporated Autologous Dendritic Cells for Stage III/IV MelanomaUniversitair Ziekenhuis Brussel · completed · Malignant Melanoma Stage III, Malignant Melanoma Stage IV · principal investigator
- Ph1NCT01066390 · A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV MelanomaBart Neyns · completed · Melanoma · principal investigator
- Ph2NCT01044225 · Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated GlioblastomaBart Neyns · terminated · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 10:48 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 471 citationsRCR 13.3
- 357 citationsRCR 8.6
- Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.J Immunother Cancer · 202197 citationsRCR 4.9
- 57 citationsRCR 1.6
- Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.J Neurooncol · 201857 citationsRCR 2.2
- Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.J Neurooncol · 201452 citationsRCR 1.5
- Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.J Neurooncol · 201648 citationsRCR 1.6
- Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx).J Immunother Cancer · 202048 citationsRCR 2.2
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.Cancer Immunol Immunother · 201639 citationsRCR 1.1
- Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.Neuro Oncol · 202430 citationsRCR 3.1